Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer
Soichiro Ako(Okayama University), Hiroyuki Okada(The University of Tokyo), Hiroshi Matushita(Okayama University), Kazuhiro Nouso(Okayama Prefecture), Sho Mizukawa(Okayama University), Takeshi Tomoda(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Saimon Takada(Okayama University), Hiroyuki Terasawa(Okayama University), Hironari Kato(Okayama University), Daisuke Uchida(Okayama University), Shinichiro Muro(Okayama University), Hideaki Kinugasa(Okayama University), Shigeru Horiguchi(Okayama University), Yosuke Saragai(Okayama University), Kazuyuki Matsumoto(Okayama University Hospital), Yuzo Umeda(Okayama University), Takahito Yagi(Okayama University), Ryuichi Yoshida(Okayama University)
Cited by 18
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
The Subaru FMOS galaxy redshift survey (FastSound). IV. New constraint on gravity theory from redshift space distortions at<i>z</i>∼ 1.4
|Publications of the Astronomical Society of Japan|2016|245
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size
|The American Journal of Gastroenterology|2006|165